New drug combo aims to outsmart tough breast cancer
Disease control
Recruiting now
This study is testing if adding a newer drug called elacestrant to the standard treatment olaparib works better for controlling advanced breast cancer in people with specific BRCA gene mutations. About 176 participants will be randomly assigned to receive either the two-drug comb…
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC